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ABSTRACT
Two major barriers to cancer immunotherapy include
tumor-induced immune suppression mediated by
myeloid-derived suppressor cells and poor immunoge-
nicity of the tumor-expressing self-antigens. To over-
come these barriers, we reprogrammed tumor-immune
cell cross-talk by combined use of decitabine and
adoptive immunotherapy, containing tumor-sensitized
T cells and CD25+ NKT cells. Decitabine functioned to
induce the expression of highly immunogenic cancer
testis antigens in the tumor, while also reducing the
frequency of myeloid-derived suppressor cells and the
presence of CD25+ NKT cells rendered T cells, resistant
to remaining myeloid-derived suppressor cells. This
combinatorial therapy significantly prolonged survival of
animals bearing metastatic tumor cells. Adoptive immu-
notherapy also induced tumor immunoediting, resulting
in tumor escape and associated disease-related mor-
tality. To identify a tumor target that is incapable of
escape from the immune response, we used dormant
tumor cells. We used Adriamycin chemotherapy or
radiation therapy, which simultaneously induce tumor
cell death and tumor dormancy. Resultant dormant
cells became refractory to additional doses of Adriamy-
cin or radiation therapy, but they remained sensitive to
tumor-reactive immune cells. Importantly, we discov-
ered that dormant tumor cells contained indolent cells
that expressed low levels of Ki67 and quiescent cells that
were Ki67 negative. Whereas the former were prone
to tumor immunoediting and escape, the latter did not
demonstrate immunoediting. Our results suggest that
immunotherapy could be highly effective against
quiescent dormant tumor cells. The challenge is to
develop combinatorial therapies that could establish a
quiescent type of tumor dormancy, which would be the
best target for immunotherapy. J. Leukoc. Biol.
100: 625–635; 2016.
Introduction
MDSCs are key cellular suppressors of anti-tumor immune
responses in breast cancer patients. Tumor-derived factors drive
the accumulation of MDSCs in the bone marrow and
secondary lymphoid organs and at the site of the tumor, thereby
inhibiting the efﬁcacy of cellular immunotherapy against
established tumors. A number of strategies have been used to
enhance immunotherapy of cancer by overcoming MDSCs.
These strategies fall into 3 major categories that include MDSC
deactivation, depletion of MDSCs, or conversion of MDSCs to
APCs [1, 2]. The latter approach identiﬁed NKT cells as a key
facilitator in promoting MDSC maturation into mature myeloid
cells with anti-tumor immune stimulatory function. Therefore,
it was suggested that the term Mregs better represents the
plasticity of these cells, rather than MDSCs [3]. With the use of
PBMCs of patients with early-stage breast cancer, we demon-
strated previously that an optimal frequency of CD25+ NKT cells
within reprogrammed immune cells, cultured in the presence
of MDSCs/Mregs, induced them to lose/down-regulate CD11b,
which was associated with HLA-DR up-regulation. Such phenotypic
modulation was shown to promote anti-human epidermal growth
factor receptor 2/neu immune responses in vitro [4]. Therefore,
inclusion of CD25+ NKT cells in AIT should enhance the anti-tumor
1. Correspondence: Tumor Microenvironment and Metastasis Program, The
Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA. E-mail:
kpayne@wistar.org; Twitter: http://www.twitter.com/@kylepayne
2. Correspondence: Dept. of Microbiology & Immunology, VCU School of
Medicine, Massey Cancer Center, 401 College St., Richmond, VA 23298,
USA. E-mail: masoud.manjili@vcuhealth.org; Twitter: http://www.twitter.
com/mmanjili1
This is an Open Access article distributed under the terms of the Creative
Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.
org/licenses/by/4.0/) which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Abbreviations: ADR = Adriamycin, AIT = adoptive immunotherapy, Aza =
azacytidine, CTA = cancer testis antigen, CYP = cyclophosphamide,
Dec = decitabine, FVS = fixable viability stain, FVS2 = FVS-negative, i.d. =
intradermally, IHC = immunohistochemistry, i.p. = intraperitoneally, i.v.,
intravenously, Ki672 = Ki67-negative, Ki67+/low = low levels of Ki67,
MDSC = myeloid-derived suppressor cell, MFI = mean fluorescence intensity,
(continued on next page)
The online version of this paper, found at www.jleukbio.org, includes
supplemental information.
0741-5400/16/0100-625 © The Author(s) Volume 100, September 2016 Journal of Leukocyte Biology 625
 Vol.100,  No.3 , pp:625-635, February, 2017Journal of Leukocyte Biology. 128.172.27.214 to IP www.jleukbio.orgDownloaded from 
efﬁcacy of adoptively transferred T cells by modulating MDSCs/Mregs
to become immunostimulatory instead of immunosuppressive.
Another barrier to successful cancer immunotherapy is that
human cancers are usually poorly immunogenic, with the
exception of melanoma. Therefore, the enhancement of the
immunogenicity of tumor cells could make them better targets for
immunotherapy. On the other hand, tumor immunoediting, such
as loss of tumor antigens and engagement of the PD-1/PD-L1
pathway, is likely to occur in the face of robust anti-tumor immune
responses. Therefore, the overcoming of tumor immunoediting
and escape remains a major challenge for effective anti-cancer
immunotherapies. To this end, it is critical to determine how
tumors may or may not be prone to immunoediting and escape
and how this tendency can be altered.
To address these challenges, we sought to modulate tumor-
immune cross-talk by using reprogrammed T cells and NKT cells
along with Dec. AIT, with reprogrammed, tumor-sensitized
T cells and CD25+ NKT cells, is expected to overcome MDSCs
and establish memory responses [5], whereas Dec is expected to
render tumor cells highly immunogenic by the induction of
the expression of CTAs [6, 7]. Dec is an epigenetic therapy for
acute myeloid leukemia, which may also inhibit the suppressive
function of MDSCs [8]. We evaluated this combinatorial
therapy against established primary tumors and against experi-
mental metastasis. Furthermore, we identiﬁed 2 types of tumor
dormancy, which included indolent dormancy characterized
by Ki67+/low and quiescent dormancy characterized by Ki672.
We demonstrated that quiescent, but not indolent, dormant
tumor cells were resistant to immunoediting.
MATERIALS AND METHODS
Mouse model
FVBN202 transgenic female mice (The Jackson Laboratory, Bar Harbor, ME,
USA) were used. These mice overexpress the nonmutated, nonactivated rat neu
transgene under the regulation of the mouse mammary tumor virus promoter
[9]. These mice develop premalignant mammary hyperplasia similar to ductal
carcinoma in situ before the development of spontaneous carcinoma [10].
These studies have been reviewed and approved by the Institutional Animal
Care and Use Committee at Virginia Commonwealth University.
Tumor cell lines
The neu-overexpressing MMC cell line was established from spontaneous
mammary tumors harvested from FVBN202 mice [11]. Tumor cells were
maintained in RPMI 1640, supplemented with 10% FBS.
Ex vivo reprogramming and expansion of splenocytes
The reprogramming of tumor-sensitized immune cells was performed as
described previously by our group [5]. In brief, FVBN202 transgenic mice
were inoculated in the mammary fat pad with 3 3 106 MMC cells. Tumor
growth was monitored by digital caliper, and tumor volumes were calculated
by v = (L 3 W2)/2, where v is volume, L is length, and W is width. As
described previously [11], splenocytes were harvested 21–25 d after tumor
challenge, when the tumor had reached $1000 mm3. Splenocytes were then
cultured in complete medium [RPMI 1640, supplemented with 10% FBS,
L-glutamine (2 mM), 100 U/ml penicillin, and 100 mg/ml streptomycin]
and were stimulated with Bryostatin 1 (2 nM; Sigma-Aldrich, St. Louis, MO,
USA), ionomycin (1 mM; Calbiochem, EMD Millipore, Billerica, MA, USA),
and 80 U/ml/106 cells of IL-2 (PeproTech, Rocky Hill, NJ, USA) for 16–18 h.
Lymphocytes were then washed thrice and cultured at 106 cells/ml in
complete medium with IL-7 and IL-15 (20 ng/ml each cytokine; PeproTech).
After 24 h, 20 U/ml IL-2 was added to the complete medium. The following day,
the cells were washed and cultured at 106 cells/ml in complete medium with
40 U/ml IL-2. After 48 h, cells were washed and cultured at 106 cells/ml in
complete medium with 40 U/ml IL-2. Twenty-four hours later, lymphocytes were
again washed and cultured at 106 cells/ml in complete medium with 40 U/ml
IL-2. Lymphocytes were harvested 24 h later on the sixth day and were then used
for in vitro studies or in vivo for AIT.
Adoptive cellular immunotherapy
Twenty-four hours before AIT, FVBN202 mice were injected i.p. with CYP
(100 mg/kg) to induce lymphopenia. Individual groups of mice were
challenged i.d. in the mammary gland region, with 3 3 106 MMC cells, or i.v.
with 106 MMC. Individual groups of mice then received reprogrammed
splenocytes i.v. at a dose of 70 3 106/mouse, 3 d after tumor challenge when
the tumor became palpable (50–70 mm3) or on the day of the i.v. tumor
injection. Untreated tumor-bearing mice served as control.
In vitro and in vivo induction of CTA expression in
MMC cells and cDNA synthesis
MMC cells (3 3 106 cells/3 ml) were cultured in the presence of 3 mM
Dec (Sigma-Aldrich) for 72 h. Medium was then removed, and cells were
washed with sterile PBS and then treated with TRIzol (Life Technologies,
Thermo Fisher Scientiﬁc, Grand Island, NY, USA), per the manufacturer’s
instructions. In vivo, FVBN202 mice, bearing primary tumor$1000 mm3, were
injected i.p. with a high-dose Dec (2.5 mg/kg), once daily for 5 d. Mice
were euthanized, and tumors were harvested 3 d later, minced, and then
treated with TRIzol, per the manufacturer’s instructions. Contaminant DNA
was then removed by DNase I digestion from the in vitro and in vivo
specimens; RNA was then puriﬁed, followed by cDNA synthesis, as described
previously by our group [12].
Real-time qRT-PCR for the detection of
CTA expression
qRT-PCR was performed in triplicate wells using the SensiMix SYBR &
Fluorescein Kit, according to the manufacturer’s procedure (Bioline,
Taunton, MA, USA), with the CFX96 Real-Time PCR Detection System (Bio-
Rad Laboratories, Hercules, CA, USA). qRT-PCR was performed using
primers speciﬁc for 6 murine CTAs and murine GAPDH. The reaction was
initiated by a denaturing period of 10 min at 95°C, followed by 40 cycles
of 95°C for 15 min, 60°C for 30 min, and 72°C for 15 min [6, 12]. Relative
CTA expression was computed after normalization to GAPDH using the
DD quantiﬁcation cycle method.
IFN-g ELISA
Reprogrammed immune cells were cultured in complete medium with
irradiated (140 Gy) MMC cells or irradiated CTA-expressing MMC, induced
by Dec treatment in vitro at a 10:1 ratio for 20 h. Supernatants were then
collected and stored at280°C until assayed. IFN-g was detected using a mouse
IFN-g ELISA kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the
manufacturer’s protocol [5].
Characterization of splenocytes and
tumor-inﬁltrating leukocytes
Spleens and metastatic tumor lesions of FVBN202 mice were harvested
when the animals became moribund and were then separately homogenized
(continued from previous page)
MMC = mouse mammary carcinoma, Mreg = myeloid regulatory cell, PD-1 =
programmed death 1, PD-L1 = programmed death ligand 1, PI = propidium
iodide, qRT-PCR = quantitative RT-PCR, RT = radiation therapy, TIL =
tumor-infiltrating lymphocyte
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into a single cell suspension as described previously [11] and below.
Splenocytes were then characterized using ﬂow cytometry. Reagents used
for ﬂow cytometry include the following: anti-CD16/32 antibody (clone
93), FITC-CD3 (17A2); FITC-CD11b (M1/70); FITC-anti-mouse IgG
(Poly4053); PE-GR-1 (RB6-8C5); PE-PD-1 (RMP1-30); PE-CD25 (3C7);
PE-Ki67 (16A8); allophycocyanin-CD49b (DX5); allophycocyanin-CD62
ligand (MEL-14); allophycocyanin-Annexin V; PerCP/CY5.5-CD4
(GK1.5); PE/CY7-CD8a (53-6.7); Brilliant Violet 421-PD-L1 (10F.9G2);
Brilliant Violet 605-CD45 (30-F11); and PI, all of which were purchased
from BioLegend (San Diego, CA, USA). BD Horizon V450-Annexin V and
FITC-FVS were purchased from BD Biosciences. Anti-rat neu antibody
(anti–c-Erb2/c-Neu; 7.16.4), was purchased from Calbiochem. All
reagents were used at the manufacturer’s recommended concentration.
Cellular staining was performed as described previously by our group [11]
or as recommended by the manufacturer (Ki67, FVS). Multicolor data
acquisition was performed using a LSRFortessa X-20 (BD Biosciences).
Data were analyzed using FCS Express v4.07 (De Novo Software, Glendale,
CA, USA).
Isolation and characterization of lung metastases
Lungs were harvested from the "Control" and "AIT" groups after
animals became moribund. Metastatic lesions were excised individually
from the residual lung tissue and minced and digested in Trypsin-
EDTA (0.25%; Life Technologies, Thermo Fisher Scientiﬁc) overnight
at 4°C. The following day, the suspension was incubated at 37°C for
30 min, followed by gentle tissue homogenization to create a cellular
suspension. The cell suspension was then washed twice with RPMI
supplemented with 10% FBS. Residual RBCs were then lysed using
ammonium-chloride-potassium lysing buffer, followed by an additional
wash with RPMI 10% FBS. The cell suspension was then placed in cell
culture and cultured with RPMI 10% FBS. Adherent metastatic tumor
cells were then characterized for the expression of rat neu and PD-L1
using ﬂow cytometry.
Characterization of metastatic tumor-
inﬁltrating leukocytes
Lungs from each group were harvested, and metastatic lesions were isolated
as described above. After tissue digestion of the metastatic lesions and
RBC lysis, 106 cells of the suspension were placed in ﬂow tubes and stained
for surface molecules as described above. All analysis was performed by gating
on viable leukocytes (Annexin V2 CD45+), thereby discriminating against
apoptotic cells and tumor cells.
Establishment of ex vivo tumor cell dormancy
MMC cells were treated with 3 daily doses of ADR (doxorubicin hydrochlo-
ride, 1 mM/d for 2 h; Sigma-Aldrich). Residual, dormant MMC cells
remained adherent to tissue-culture ﬂasks, whereas the MMC cells susceptible
to ADR therapy became nonadherent and were removed from the culture
periodically. Assessment of viability, Ki67 expression, and IFN-g-induced
PD-L1 up-regulation by ﬂow cytometry occurred 3 wk after the ﬁnal
treatment. Likewise, 3 daily doses of RT (2 Gy/d) were also used to establish
dormant MMC cells. ADR and RT-induced dormant MMC cells were used in
the cytotoxicity assay, 8 d after the ﬁnal treatment.
IHC
Sections of formalin-ﬁxed parafﬁn-embedded tissue from each tumor
were stained with H&E to examine the histomorphology. Additional
sections are then subsequently immunolabeled using the standard IHC
technique, using the avidin-biotin peroxidase system with a puriﬁed anti-
mouse Ki67 (BioLegend). Sections of lymph nodes were used as the
positive control. Nikon Eclipse 80i light microscope was used to examine
the H&E and IHC. The most intense labeling regions (hot spots) away
from the edge of the tissue were evaluated using IHC-positive tumor cells
as numerator and the overall tumor cells as the denominator.
Representative images of the H&E and the corresponding hotspots were
taken.
Statistical analysis
Statistical comparisons between groups were made using 1- and 2-tailed
Student’s t test. Time to death in the in vivo survival studies was calculated
from baseline to the date of death. Mice were euthanized when they had
a weight loss of $10%. Kaplan-Meier curves and log-rank tests are used
to illustrate time to death and to test the difference between each group.
P # 0.05 was considered statistically signiﬁcant.
RESULTS
The reprogramming of tumor-immune cross-talk during
immunotherapy fails to protect animals from an
established primary mammary carcinoma
We have reported previously that AIT, using reprogrammed
T cells and NKT cells in a prophylactic setting, protected
animals against primary tumors and recall tumor challenge.
This protection was associated with the presence of memory
T cells, and CD25+ NKT cells that rendered T cells resistant to
MDSC-mediated suppression [5]. Here, we sought to de-
termine whether AIT as a single therapy can protect animals
against established primary mammary carcinoma by over-
coming MDSCs. FVBN202 mice bearing primary tumors
received AIT using reprogrammed T cells and CD25+
NKT cells when the tumor had reached 50–70 mm3 or
remained untreated. As shown in Fig. 1A and B, AIT alone
did not slow the rate of tumor growth (Fig. 1A) or improve
overall survival (Fig. 1B) in recipient mice compared with
untreated control mice. Then, we combined AIT with
epigenetic modulation of tumor cells in vivo to enhance
immunogenicity of tumor cells, as well as eliminate MDSCs.
To do so, tumor-bearing animals received Dec before AIT.
Use of Dec induced the expression of a panel of CTAs in
tumor cells (Fig. 1C and D) and resulted in the elimination of
MDSCs (Fig. 1E; P = 0.034). However, AIT still failed to
protect animals from established primary tumors when
compared with Dec alone (Fig. 1F and G). This failure was
observed in spite of successful reprogramming of tumor-
sensitized immune cells (Supplemental Fig. 1) and their
enhanced reactivity against CTA-expressing MMC (Fig. 1H;
P = 0.0001).
The reprogramming of tumor-immune cross-talk during
immunotherapy prolongs survival of animals bearing
metastatic tumor cells in their circulation
We have reported previously that administration of AIT along
with another epigenetic modulator, Aza, was effective in
prolonging survival of patients with multiple myeloma when
treatment was delivered during minimal residual disease to
prevent advanced stage disease [6]. Therefore, we sought to take
a similar approach in our experimental model of breast
cancer by administrating AIT and Dec when tumor cells were
present in the circulation and before establishing lung metastasis.
AIT alone had a marginal impact on the survival of animals,
Payne et al. Tumor immunoediting and cancer dormancy
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whereas Dec alone resulted in prolonging the survival of
animals (Fig. 2; P = 0.013). AIT + Dec was the most effective
therapy that resulted in prolonging the survival of animals
compared with the control group or Dec alone (Fig. 2; P = 0.0001
and P = 0.037, respectively). However, all animals eventually
succumbed to metastatic tumors in the lungs.
Immunotherapy induces tumor immunoediting and
escape in proliferating tumor cells and indolent
dormant cells but not in quiescent dormant cells
To determine whether reprogrammed memory T cells were
maintained in vivo, splenocytes of AIT recipients were collected
when mice became moribund and cultured with MMC tumor
Figure 1. AIT, with or without Dec, fails to induce regression-established mammary carcinoma. (A and B) Animals were challenged with MMC (3 3 106) i.d.
in the mammary gland region; upon the tumor reaching 50–70 mm3, animals were conditioned with CYP (100 mg/kg). The following day, mice remained
untreated (Control; n = 4) or received AIT (n = 4). (C) MMC tumor cells were cultured with (+Dec) or without Dec (Untreated; 3 mM) for 72 h; RNA was
then extracted and converted to cDNA, followed by qRT-PCR, using primers speciﬁc for 6 murine CTAs. (D) Tumor-bearing (;1000 mm3 i.d.) FVBN202
mice received 5 injections of Dec, 1/d (+Dec; 2.5 mg/kg; n = 1) or remained untreated (n = 1); the tumors were harvested 3 d later, and cDNA was
generated to quantify CTA expression, which was normalized to GAPDH. AKAP4, A-kinase anchor protein 4; ESX1, ; MAGEA4, melanoma-associated
antigen 4; MAGEB5, melanoma-associated antigen B5; SPA17, ESX1, Extraembryonic, spermatogenesis, homeobox 1; SPA17, Sperm Autoantigenic Protein
17. (E) Animals were challenged i.d. with MMC (3 3 106) in the mammary gland region; after tumors reached 50–70 mm3, all animals were treated with
Dec (every other day for 3 total injections; 2.5 mg/kg, i.p.; n = 3) or remained untreated (n = 3). Seven days later, mice were euthanized, and MDSCs were
analyzed in the spleen. (F and G) Animals were challenged i.d. with MMC (3 3 106) in the mammary gland region; after tumors reached 50–70 mm3, all
animals were treated with Dec [every day for 3 total injections (33); 2.5 mg/kg, i.p.]. Two days later, animals were conditioned with CYP (100 mg/kg, i.p.).
The following day, mice remained untreated (Control; n = 3) or received AIT (n = 4), derived from a CTA+ tumor-bearing donor. (H) MMC cells
remained untreated (MMC) or were treated with Dec (3 mM; 72 h) to induce CTA expression (CTA-MMC). Tumor cells were then cocultured with
reprogrammed splenocytes (1:10) for 20 h. IFN-g was detected in the supernatant by ELISA. Data represent means 6 SEM of duplicate wells.
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cells. As shown in Fig. 3A, tumor-reactive IFN-g production by
endogenous splenic T cells from the AIT group was greater
than that produced by T cells from the control group
(P = 0.003). To determine the impact of treatments on tumor
immunoediting and escape, T cells and tumor cells in the
tumor-microenvironment of the lung were analyzed. Meta-
static tumor lesions were isolated from the lung at the end of
the trial and analyzed for the expression of the tumor
antigen, neu, and PD-L1. The tumor lesions isolated from
the AIT group showed down-regulation of neu antigen on the
tumor cells compared with control MMC tumor cells and the
lesions isolated from the control group (Fig. 3B, upper;
P = 0.00003 and P = 0.0008, respectively). The AIT + Dec
group showed similar trends as the AIT group. Additionally,
25% of MMC cells isolated from metastatic tumor lesions of
the AIT group demonstrated total loss of neu expression
compared with control MMC tumor cells and the lesions
isolated from control group (Fig. 3B, lower; P = 0.002 and
P = 0.01, respectively). Again, the AIT + Dec group showed
similar trends as the AIT group. This suggests that metastatic
MMC cells may eventually escape detection from neu-speciﬁc
cellular immunity. Metastatic tumors of the control group
that received no treatment did not show down-regulation or
loss of neu antigen (Fig. 3B). As AIT was the major factor
in neu loss/down-regulation, and the AIT-Dec group showed
a similar trend, we looked at the expression of tumor PD-L1
expression in the AIT group. Interestingly, metastatic tumor
cells from the control group had higher expression of PD-L1
in the tumor compared with the metastatic tumor cells from
the AIT group or control MMC cells (Fig. 3C; MFI: 1360 vs.
390 6 SEM; P = 0.011). A similar trend was observed when
MMC cells were cultured with IFN-g or splenocytes of tumor-
bearing animals (Fig. 3D).
The immune-suppressive function of PD-L1 requires engage-
ment with PD-1, which renders immune cells unresponsive
[13, 14]. Importantly, 40–50% of reprogrammed T cells and
NKT cells that were used for AIT expressed PD-1 (Fig. 3E), but
only CD8+ T cells were observed to up-regulate PD-1 as a result
of reprogramming (Fig. 3E; P = 0.01). Therefore, we also
analyzed tumor-inﬁltrating T cells for PD-1 expression to
determine the potential for the PD-1/PD-L1 axis to mediate
T cell suppression within the tumor site. Interestingly, as seen in
Fig. 3F, tumor inﬁltration of CD8+ T cells into the tumor bed
was greater in mice receiving AIT compared with untreated mice
(14% vs. 3%, respectively; P = 0.02). However, expression of
PD-1 on tumor-inﬁltrating CD8+ T cells did not signiﬁcantly
increase following AIT compared with the control group (Fig.
3G). We did not observe CD4+ T cell inﬁltration into the tumor
lesions (data not shown). Splenic T cells and NKT cells that
were isolated from the AIT and control groups when animals
became moribund also expressed PD-1, although there was no
statistical difference between the groups (Fig. 3H; 10% of
T cells and 50% of NKT cells). Taken together, these data suggest
that although AIT promotes the inﬁltration of CD8+ T cells,
the highly proliferative nature of the metastatic tumors may
evade such anti-tumor immune responses by emerging with
reduced expression of the tumor antigen, neu. Metastatic tumor
of the Dec group also showed down-regulation of neu antigen
(Supplemental Fig. 2A, left; MFI: 442 vs. 202 6 SEM), as well as
total loss of neu antigen in 36% of tumor cells compared with
the control MMC cell line containing a residual 5% of neu-
negative cells (Supplemental Fig. 2A, right). As the control group
did not show neu loss or down-regulation, but the AIT group
did, we sought to determine whether neu loss or down-regulation
in animals who received Dec could result from the
contribution of an endogenous T cell response induced by Dec,
which induces the expression of CTAs and therefore, could
function as an in situ vaccination by eliciting endogenous T cell
responses. To determine the contribution of Dec in neu
antigen loss or down-regulation, we performed in vitro studies by
treatment of MMC with Dec alone, where the endogenous
immune response did not have any contribution. Dec treatment
resulted in the quantitative down-regulation of neu expression
but did not induce total neu loss (Supplemental Fig. 2B;
P = 0.008). IFN-g induced down-regulation of neu (Supplemental
Fig. 2C; P = 0.002), and Dec did not recover neu expression.
Thus, we then began to question whether residual tumor cells
that remain after conventional cytotoxic therapy, which are
generally dormant, also use similar escape mechanisms or if
they were perhaps more sensitive to immune-mediated
elimination.
To determine whether dormant tumor cells were resistant to
immunoediting and escape, MMC tumor cells were treated
with ADR to establish tumor dormancy ex vivo. Dormant
tumor cells were then treated with a product of anti-tumor
T cell responses—IFN-g—to determine sensitivity of different
dormant cells, quiescent and indolent, to immunoediting. We
looked at the expression of PD-L1, as this is the most
immediate immunoediting change that occurs as a result of
IFN-g treatment. A clinically relevant proliferation marker,
Ki67, along with a viability marker (FVS), was used to detect
Figure 2. Combined use of Dec and AIT prolongs survival of animals
and induces tumor immune editing. FVBN202 mice were challenged
with 1 3 106 MMC cells i.v. Mice then remained untreated (Control;
n = 4), received AIT (n = 7) on the same day as tumor challenge,
received Dec (Dec; n = 4; 5 daily doses beginning on d 3 after tumor
challenge), or received Dec and AIT (AIT + Dec; n = 6; AIT on the day
of tumor challenge, followed by Dec beginning on d 3).
Payne et al. Tumor immunoediting and cancer dormancy
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FVS2 viable, indolent tumor cells (Ki67+/low) and quiescent
tumor cells (Ki672). As shown in Fig. 4A, ADR induced
apoptosis in the majority of MMC cells, such that by 3 wk
after treatment, the number of FVS2 viable MMC cells was
reduced from 77% to 31% (P = 0.005). The remaining
residual viable tumor cells that escaped ADR-induced
apoptosis entered a state of dormancy, as there was no
signiﬁcant increase in the number of tumor cells between
1 and 3 wk after completion of ADR treatment (Fig. 4B). To
determine if dormant tumor cells could exploit immune
escape mechanisms, we established ADR-induced tumor
dormancy, followed by treatment of dormant MMC cells with
IFN-g, 3 wk after the completion of ADR treatment to
provoke PD-L1 expression [15]. We evaluated the expression
of PD-L1 on viable proliferating control MMC cells (Ki67+),
without (Untreated) and with IFN-g (Untreated → IFN-g)
treatment, as well as on viable dormant tumor cells without
(+ADR) and with IFN-g (+ADR→ IFN-g) treatment. As shown
in Fig. 4C, left, ADR-treated MMC showed a signiﬁcant shift
from Ki67+ toward Ki67+/low cells (P = 0.026), indicative of
indolent tumor dormancy. ADR or ADR → IFN-g treatment
also resulted in a shift from Ki67+ toward Ki672 quiescent
cells, as shown by an increased frequency of Ki672 MMC (Fig.
4C; P = 0.02 and P = 0.001, respectively) and a decreased
Figure 3. AIT promotes immunoediting of lung metastatic lesions. (A) Splenocytes were harvested from untreated mice (Control; n = 5) and AIT
recipients (n = 3) and cultured in the presence of MMC cells (10:1) for 20 h. Supernatants were collected and subjected to IFN-g ELISA. (B)
Metastatic lesions in the lung of FVBN202 mice that remained untreated (Control; n = 3), AIT recipients (n = 6), and AIT + Dec recipients (n = 4)
were harvested when mice became moribund. Tumor lesions were digested and analyzed. MFI of neu and frequency of neu loss (B) and MFI of PD-
L1 (C) were then quantiﬁed using ﬂow cytometry using MMC cell line (MMC) as an in vitro control. (D) MMC cells were cultured with IFN-g or
splenocytes of tumor-bearing mice, and PD-L1 was detected after 16–20 h (n = 2–3). (E) Spleens of FVBN202 mice bearing primary mammary
carcinoma (n = 4) were harvested after tumors were $1000 mm3. PD-1 expression was then quantiﬁed on the splenocytes, pre- and
postreprogramming. (F and G) Metastatic lesions in the lung of FVBN202 mice that remained untreated (Control) and AIT recipients were
harvested when mice became moribund. (F) The frequency of CD8+ T cell inﬁltration metastatic lesion in the lung of control mice and the AIT
group (n = 3) was determined on gated CD3+ cells. SSC-A, Side-scatter-area. (G) Expression of PD-1 was determined on CD3+CD8+ cells (Control,
n = 1; AIT, n = 3) by gating on CD45+ viable leukocytes. (H) Spleens of FVBN202 mice that had received AIT (n = 4) or remained untreated
(n = 3) and were i.v. challenged with MMC were analyzed by ﬂow cytometry after tumor-bearing mice became moribund to quantify PD-1
expression. Data represent means 6 SEM.
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Figure 4. ADR treatment results in the emergence of indolent and quiescent tumor dormancy. (A) MMC tumor cells were treated with 3 daily doses
of ADR (1 mM for 2 h) and then remained untreated for 3 wk. The frequency of viable MMC cells was determined by quantifying FVS2 cells using
ﬂow cytometry. (B) At wk 1 and 3 post-treatment, adherent and viable tumor cells were counted by trypan blue exclusion. (C and D) MMC cells
were treated for 3 consecutive d with ADR (1 mM, 2 h) or left untreated. Three weeks later, ADR-treated and untreated MMC cells were stimulated
with IFN-g (50 ng/ml) for 12–16 h to induce the expression of PD-L1. (C) Emergence of Ki67 was determined in control MMC cells (Untreated),
as well as ADR-treated cells (+ADR) 6 IFN-g stimulation. (D) The expression of PD-L1/cell was calculated by dividing PD-L1 MFI by the frequency
of Ki672 cells in ADR-treated and untreated MMC cells 6 IFN-g stimulation. Data represent 3 independent experiments and means 6 SEM.
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frequency of Ki67+ MMC cells (Fig. 4C; P = 0.02 and P = 0.001,
respectively). IFN-g treatment induced up-regulation of
PD-L1 on Ki67+/low indolent MMC (Fig. 4D, left; P = 0.002
and P = 0.01). Interestingly, Ki672 control MMC cells and
Ki672 quiescent MMC cells did not up-regulate PD-L1 in the
presence of IFN-g (Fig. 4D, right).
Dormant MMC cells established by ADR or RT become
resistant to higher doses of chemotherapy or RT but
remain sensitive to immunotherapy
ADR chemotherapy usually induces tumor dormancy, which
could lead to tumor recurrence. To determine the direct effect
of ADR on tumor dormancy, we performed ex vivo experiments.
ADR treatment increased the proportion of Ki672 tumor cells,
which lasted for 3 wk. This trend was associated with reduced
viability, 3 wk after treatment, which improved 6 wk after
treatment (Supplemental Fig. 3; 77% . 31% . 50%). To
determine whether dormant MMC cells established by ADR
treatment remain sensitive to tumor-reactive immune cells,
dormancy was established by treating MMC with 3 daily doses
of ADR (1 mM/d for 2 h; Supplemental Fig. 4A); 8 days after the
ﬁnal treatment, MMC cells received a high dose of ADR
(1 mM for 24 h) or were cultured with tumor-reactive immune
cells for 48 h. ADR treatment induced apoptosis in MMC cells
Figure 5. Immunotherapy displays cytotoxic func-
tion against treatment refractory dormant tumor
cells in vitro. (A) MMC cells (n = 3) treated with
ADR (1 mM, 2 h) or 2 Gy RT (RT-treated MMC)
for 3 consecutive d and remained in culture for
8 d total to establish tumor cell dormancy in
vitro. (B) On d 8, these dormant tumor cells were
treated with a high-dose ADR (1 mM, 24 h; ADR-
treated MMC + ADRhi) or reprogrammed im-
mune cells (ADR-treated MMC + immune cells;
ADR-treated MMC + immune cells). Two days
later, cells were stained with Annexin V/PI and
analyzed by ﬂow cytometry. Data represent 3
biologic repeats and means 6 SEM. (C) On d 8,
these dormant tumor cells were treated with 18
Gy RT (RT-treated MMC + RThi) or reprog-
rammed immune cells (RT-treated MMC + im-
mune cells). Two days later, cells were stained
with Annexin V/PI and analyzed by ﬂow cytom-
etry. (D) MMC tumor cells or dormant MMC
cells (RT-MMC, ADR-MMC) were cultured in the
absence or presence of the reprogrammed im-
mune cells in a 10:1 ratio for 24 h. Control
immune cells were cultured alone (Medium).
IFN-g release was detected in the supernatant
using ELISA. Data represent 2 biologic repeats
and means 6 SEM.
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(Fig. 5A and B; P = 0.01). Tumor cells that survived apoptosis
became chemo refractory, such that additional ADR treatment
at a higher dose (1 mM for 24 h) did not induce cell death
(Fig. 5A and B; average 40% vs. 54%). However, they remained
sensitive to tumor-reactive immune cells. In the presence of
tumor-reactive immune cells, the frequency of viable
ADR-treated dormant MMC dropped from 40% to 8% (Fig. 5A
and B; P = 0.003). In fact, lymphocytes were more effective than a
high dose of chemotherapy in inducing apoptosis in dormant
MMC (Fig. 5A and B; P = 0.02). We also established dormant
MMC by 3 daily doses of RT (2 Gy/d); again, surviving
dormant cells became refractory to RT. An additional RT at a
higher dose (18 Gy) did not markedly decrease the frequency
of viable tumor cells (Fig. 5B and C; 53% vs. 52%). However,
RT refractory MMC cells remained sensitive to tumor-
reactive lymphocytes as the viability dropped from 53% to 8%
(Fig. 5B and C; P = 0.002). In recapitulating our results with
chemotherapy-induced tumor cell dormancy, tumor-reactive
immune cells were more effective than high-dose RT at inducing
apoptosis in dormant MMC (Fig. 5B and C; P = 0.01). To
determine whether higher levels of apoptosis in dormant tumor
cells were a result of their greater sensitivity to immune cells
rather than a higher reactivity of the immune cells, IFN-g ELISA
was performed using reprogrammed immune cells cultured
with MMC tumor cells or ADR- and RT-induced dormant MMC
cells. As shown in Fig. 5D, tumor-reactive immune cells produced
comparable levels of IFN-g upon stimulation with MMC or
dormant MMC (RT-MMC, ADR-MMC). To determine the
establishment of Ki672 quiescent and Ki67+/low indolent tumor
cells, experimental animals bearing primary MMC were
treated with ADR or remained untreated. Animals treated with
ADR exhibited suppression of tumor growth (Supplemental
Fig. 4B). Tumors of the ADR group showed a shift from Ki67+
toward Ki67+/low indolent and Ki672 quiescent cells (Supple-
mental Fig. 4C).
DISCUSSION
We developed an experimental metastatic mouse model by i.v.
injection of highly proliferative MMC cells to FVBN202 mice.
Animals in this model became moribund within 20-40 d and
presented with lung metastases upon macroscopic inspection.
This model represents the onset of advanced stage disease. We
demonstrated that concurrent use of Dec with AIT using
reprogrammed CD25+ NKT and T cells prolonged survival of
the experimental animals but failed to eliminate the tumor, as
all mice eventually succumbed to metastatic disease in the
lungs. Failure of tumor elimination was associated with down-
regulation of the tumor antigen, neu, on metastatic tumor
cells. Studies involving AIT without Dec treatment in vivo or
Dec alone without immune response in vitro conﬁrmed that
total neu antigen loss and down-regulation were mediated by
anti-tumor immune responses, whereas Dec alone only had the
capacity to induce down-regulation of neu antigen. We have
reported previously that treatment of neu-negative tumor cells
(antigen-negative variant) with Dec resulted in the induction of
neu expression at mRNA but not at protein levels [11].
Likewise, Dec treatment did not overcome IFN-g-induced
down-regulation of neu protein in MMC. Here, we also showed
that a high dose of Dec induced down-regulation of the neu
protein in vivo. These data suggest that high-dose Dec might
have different effects on neu expression during mRNA
transcription and protein translation. It was reported that a low
dose of Dec could have only a hypomethylating effect when
incorporated into DNA, whereas a high-dose Dec could also
incorporate into RNA and show different effects [16].
Although Dec or Aza render tumor cells highly immunogenic
by inducing the expression of highly immunogenic CTAs, this
effect is usually transient in that tumor cells lose CTAs after the
cessation of Aza therapy [6].
We hypothesized that targeting dormant but not highly
proliferating tumor cells might overcome tumor immunoediting
and escape. Therefore, we conducted studies to determine the
sensitivity of dormant tumor cells to immunoediting and escape.
We demonstrated that ADR treatment induced 2 types of tumor
dormancy: 1) an indolent type of dormancy, characterized by the
positive/low expression of Ki67; this type of dormancy is
maintained through balanced proliferation and death, as these
cells keep producing dead cells, whereas the total number of
viable cells remains unchanged; and 2) a quiescent type of tumor
dormancy that is characterized by lack of Ki67 expression (Ki672);
this type of dormancy is maintained through total cessation of
proliferation. We demonstrated that proliferating tumor cells,
either untreated tumor cells (Ki67+) or indolent tumor cells
(Ki67+/low), were susceptible to immunoediting and escape
during cell division, but quiescent tumor cells (Ki672) failed to
undergo immunoediting; in fact, they failed to up-regulate PD-L1
in the presence of IFN-g stimulation. These results suggest that
quiescent dormant cells could be the best target for
immunotherapy.
It was reported that innate IFN-g is essential for up-
regulation of PD-L1 expression [17]. Intriguingly, an adaptive
immune response following AIT resulted in a .3-fold in-
hibition in the induction of PD-L1 expression on tumor cells
compared with the control group, although it was still
signiﬁcantly higher than MMC tumor cells in vitro before
challenge. Similar results were obtained when tumor cells were
cultured with IFN-g or lymphocytes of tumor-bearing mice.
These data suggest that a T cell-independent inﬂammatory
response, which involves IFN-g, has a greater impact than
T cells on up-regulation of PD-L1. In addition, AIT was
associated with a signiﬁcant inhibition in the induction of
tumor PD-L1 compared with no AIT control group, suggesting
that the PD-1/PD-L1 axis is more active in tumor-bearing
animals in the absence of AIT. To test this, we cocultured
reprogrammed tumor-reactive T cells with MMC in the
presence or absence of PD-1 blocking antibody; the anti-tumor
function of reprogrammed T cells was not affected by PD-1
blockade in vitro (data not shown).
This is important, as reprogrammed T cells and NKT cells
that were used for AIT expressed PD-1, and PD-1 expression was
sustained after AIT. However, reprogrammed T cells also
produce perforin and granzyme B [5], allowing them to induce
apoptosis in tumor cells before they begin to up-regulate PD-L1
mediated by IFN-g. These data suggest that AIT results in a
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signiﬁcant inhibition of tumor PD-L1 induction to the levels
that might not be suppressive. Blockade of PD-1/PD-L1 by anti-
PD-1 antibody did not have any effects on anti-tumor immune
responses against MMC in vitro (data not shown). Therefore,
prolonged survival in the AIT group could be associated with
lower expression of PD-L1 in MMC when tumor cells were
present in the circulation compared with the control group
when tumors were established in the lungs. Given the high
levels of PD-L1 expression on established tumors, administra-
tion of AIT as a single agent in a therapeutic setting is likely to
fail in curing cancer, as it was evident in our therapeutic
protocol (Fig. 1). Administration of AIT in a preventive setting,
when tumor cells were in the circulation but before they
establish lung metastasis, was highly effective, although animals
succumbed to metastatic tumor, as their tumors begin to
undergo neu antigen loss. Our data suggest that tumors use
numerous mechanisms to change during cell division and
escape from immunotherapy. These mechanisms were shown
to overcome tumor immune surveillance and reduce the
efﬁcacy of immunotherapy [18, 19]. However, and intriguingly,
dormant tumor cells that were established by chemotherapy
or RT and that became chemo resistant or RT resistant
remained sensitive to tumor-reactive immune cells. Our
ﬁndings are consistent with the reports on the efﬁcacy of AIT
in patients with metastatic melanoma using TILs grown in
IL-2. AIT, using IL-2-expanded TIL, resulted in tumor re-
gression in 49% of patients [20]. When AIT was combined
with total body irradiation, which was implemented to induce
lymphopenia, objective responses increased to 72%. Among
treated groups, 20% had complete tumor regression and
.10 y relapse-free survival [21]. Thus far, of the 34 complete
responders in the National Cancer Institute trials, 1 has
recurred [22].
The results of this study suggest that administration of
immunotherapy in a setting of advanced stage prophylaxis,
i.e., after the completion of conventional cancer therapies,
when tumor dormancy is established but before distant
recurrence of the disease, could effectively target dormant
tumor cells and prevent advanced stage disease. On the
other hand, the application of immunotherapy to highly
proliferative tumors renders the tumors prone to immuno-
editing and subsequent immunologic escape during cell
division [23]. The challenge is to develop combinatorial
therapies, i.e., AIT, following the administration of epige-
netic modulators or small molecules that could induce cell-
cycle arrest and establish a quiescent type of tumor
dormancy so as to render dormant tumor cells resistant to
immunoediting and escape from immunotherapy. The
extension of knowledge gained from our preclinical studies
to the clinical setting remains to be determined in patients
with early-stage breast cancer or patients with minimal
residual disease.
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Supplemental Figure 1. Expansion and phenotypic reprogramming of tumor-reactive 
splenocytes is similar between animals bearing primary cancer with and without 
Decitabine preconditioning. FVBN202 mice were challenged with 3 x 106 MMC cells 
intradermally. A portion of the mice went on to receive five sequential injections of Dec (2.5mg/
kg) once tumors reached 1000mm3 (+Dec), while the remaining mice were untreated (-Dec). 
Mice were euthanized and spleens were harvested 7 days after the final injection of Dec, and 
were then treated with B/I and g-c cytokines ex vivo. A) Cell counts of viable tumor-reactive 
immune cells was determined by trypan blue exclusion; fold change was calculated by 
normalizing the cell count of each day to the number of cells present on day 1. Flow cytometry 
was used to determine the frequency of total CD4+ and CD8+ T cells (B), phenotype of CD4+ 
and CD8+ T cells (C), and the frequency of CD25+ NKT cells (D). Data represent four biological 
repeats for each group and mean ± SEM.  
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Supplemental Figure 2. AIT promotes immunoediting of 
lung metastatic lesions. A) FVBN202 mice were 
challenged i.v. with MMC cells (1 x 106); 3 days later they 
were injected with Dec (2.5mg/kg) once daily for 5 days or 
remained untreated (MMC). After the mice became 
moribund, metastases were excised from the lung and 
established in vitro. Neu median fluorescence intensity (MFI) 
and percentage of neu negative cells were quantified using 
flow cytometry 10-14 days after the animals had been 
euthanized. B) MMC cells were treated with Dec (Dec; 3uM) 
or remained untreated (MMC), in vitro. After 10 days of 
culture,  neu  expression was quantified using flow 
cytometry. C) MMC cells remained untreated or were treated 
with one dose of IFN-γ (50ng/ml) or Dec+IFN-γ, in vitro. 
Expression of neu was determined 7 days after the final 
treatment. Data represent mean MFI ± SEM of triplicates.  
Supplemental Figure 3. Dormant tumor cells recover proliferative capacity as a function of time. 
MMC tumor cells were treated with 3 daily doses of ADR (1uM for 2 hs), then remained untreated for 3 
weeks and 6 weeks, in vitro. At weeks 3 and 6 post-treatment, Ki-67 expression and viability were 
quantified within the population of adherent tumor cells. Data represent 3 independent experiments and 
mean ± SEM. 
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Supplemental Figure 4. ADR treatment induces tumor dormancy. A) MMC cells (n=3) treated with ADR (1uM, 2 hs) for 
3 consecutive days and remained in culture for 8 days total, in order to establish tumor cell dormancy, in vitro. B) FVBN202 
mice were challenged with MMC (3x106) in the mammary gland region; after tumors reached 30-50 mm3 animals were 
treated with ADR (MMC+ADR; 20 mg/kg; i.v.), or remained untreated (MMC). Tumor growth was monitored for four weeks, 
C) Animals were sacrificed and tumor specimens were collected and subjected to H & E staining as well as IHC for Ki67. 
Arrows show Ki-67+ proliferating tumor cells (dark brown), Ki-67- quiescent tumor cells (blue color like background) and 
Ki-67+/low indolent tumor cells (weak brown). Figures show a 200X magnification. 
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